RISK OF THERAPY-RELATED LEUKAEMIA AND PRELEUKAEMIA AFTER HODGKIN'S DISEASE
- 1 July 1987
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 330 (8550), 83-88
- https://doi.org/10.1016/s0140-6736(87)92744-9
Abstract
No abstract availableThis publication has 45 references indexed in Scilit:
- Leukemia after Adjuvant Chemotherapy with Semustine (Methyl-CCNU) — Evidence of a Dose–Response EffectNew England Journal of Medicine, 1986
- Leukemia and Preleukemia after Adjuvant Treatment of Gastrointestinal Cancer with Semustine (Methyl-CCNU)New England Journal of Medicine, 1983
- Acute Nonlymphocytic Leukemia after Therapy with Alkylating Agents for Ovarian CancerNew England Journal of Medicine, 1982
- Incidence of Acute Nonlymphocytic Leukemia, Preleukemia, and Acute Myeloproliferative Syndrome up to 10 Years after Treatment of Hodgkin's DiseaseNew England Journal of Medicine, 1982
- Increased Incidence of Acute Leukemia in Polycythemia Vera Associated with Chlorambucil TherapyNew England Journal of Medicine, 1981
- The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute LeukemiaNew England Journal of Medicine, 1979
- Occurrence of Non-Hodgkin's Lymphoma after Therapy for Hodgkin's DiseaseNew England Journal of Medicine, 1979
- Acute leukaemia after busulphan.BMJ, 1977
- Acute Leukemia after Alkylating-Agent Therapy of Ovarian CancerNew England Journal of Medicine, 1977
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958